Relmada Therapeutics RLMD
NASDAQ RLMD
$3.21 -0.15 (-4.46%)
At close: Oct 21, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) Receivables - Net (2022 - 2026)

Updated

Relmada Therapeutics' Receivables - Net was $10,912 in Q2 2026.

Analysis

Relmada Therapeutics (RLMD) Receivables - Net (2022 - 2026) Analysis & Trends

At the end of FY2022, Receivables - Net at Relmada Therapeutics came in at $512,432.

  • The Q2 2026 figure marks the highest quarterly Receivables - Net since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Relmada Therapeutics 361.29 Mn -197.30 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10,912.00
Dec 31, 2022 512,432.00
API Access

Relmada Therapeutics Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=RLMD&period=max&api_key=YOUR_API_KEY